Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women~2. Age 18 years and older~3. Spinal cord injury within 8 weeks of study entry~4. ASIA AIS A or B~5. Medically stable in the opinion of their physiatrist~6. Able to have dexa performed~7. Able to return for follow-up at 6 and 12 months~Exclusion Criteria:~1. Vitamin D deficiency~2. Hypocalcemia~3. Renal insufficiency (estimated creatinine clearance \<30ml/min)~4. Abnormal thyroid hormone status~5. Abnormal mental status~6. Osteoporosis at the hip or spine by dexa

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- zoledronic acid (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).